Trevena (NYSE: TRVN) — Perfil da empresa, notícias e dados financeiros
Trevena develops treatments for CNS disorders, notably OLINVYK for acute pain management, advancing innovative therapies for unmet needs.
Trevena
Trevena (NASDAQ:TRVN) specializes in developing innovative treatments targeting central nervous system (CNS) disorders, aiming to provide novel therapies for conditions with significant unmet medical needs. Its diverse portfolio includes several in-development drugs designed to tackle pain management, acute heart failure, and other critical areas. A notable project is OLINVYK, a U.S. FDA-approved intravenous opioid designed for acute pain management in adult patients, exemplifying Trevena's commitment to addressing challenging health care issues. With a focus on leveraging its proprietary platform to discover and advance new therapeutics, Trevena's objective remains firmly on enhancing patient care through scientific innovation and strategic partnerships.
Resumo
Operações
Produtos e/ou serviços de Trevena
- OLINVYK (oliceridine) is an opioid agonist for the management of moderate to severe acute pain in adults for whom an intravenous opioid is warranted.
- TRV027 is a novel AT1 receptor selective agonist aimed at treating acute lung injury including that caused by COVID-19.
- TRV734 is a biased ligand targeting the mu-opioid receptor, developed for the potential treatment of pain without the side effects of traditional opioids.
- TRV250 is a delta receptor agonist for the treatment of refractory migraine, designed to offer pain relief without the risk of addiction.
- The company's early-stage research focuses on discovering and developing novel biased ligands targeting G protein-coupled receptors (GPCRs) to address unmet medical needs in CNS disorders.
- They are exploring the use of their proprietary platform technology to develop S1P receptor modulators for the treatment of autoimmune and inflammatory diseases.
equipe executiva do Trevena
- Ms. Carrie L. BourdowPresident, CEO & Chairman
- Dr. Mark A. Demitrack M.D.Senior VP & Chief Medical Officer
- Dr. Howard A. Rockman M.D.Scientific Founder, Consultant and Member of Scientific Advisory Board
- Ms. Katrine SuttonPrincipal Financial Officer & principal accounting officer
- Mr. Robert T. YoderSenior VP, Chief Business Officer, Head of Commercial Operations & Chief Compliance Officer
- Mr. Michael CatalanoVice President of Marketing
Principais indicadores financeiros
Resultados divulgados pela Trevena, em USD.
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 3,1 mi | -35,3 mi | -40,3 mi | |
| -418 mil | -56,4 mi | -53,7 mi | |
| 567 mil | -51,9 mi | -51,2 mi | |
| 3,1 mi | -29,5 mi | -29,4 mi |